281 related articles for article (PubMed ID: 27737555)
1. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.
Kumar M; Singh K; Naran K; Hamzabegovic F; Hoft DF; Warner DF; Ruminski P; Abate G; Chibale K
ACS Infect Dis; 2016 Oct; 2(10):714-725. PubMed ID: 27737555
[TBL] [Abstract][Full Text] [Related]
2. Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis.
Kumar M; Singh K; Ngwane AH; Hamzabegovic F; Abate G; Baker B; Wiid I; Hoft DF; Ruminski P; Chibale K
Bioorg Med Chem; 2018 Feb; 26(4):833-844. PubMed ID: 29373270
[TBL] [Abstract][Full Text] [Related]
3. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.
Machado D; Couto I; Perdigão J; Rodrigues L; Portugal I; Baptista P; Veigas B; Amaral L; Viveiros M
PLoS One; 2012; 7(4):e34538. PubMed ID: 22493700
[TBL] [Abstract][Full Text] [Related]
4. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs.
Gupta AK; Katoch VM; Chauhan DS; Sharma R; Singh M; Venkatesan K; Sharma VD
Microb Drug Resist; 2010 Mar; 16(1):21-8. PubMed ID: 20001742
[TBL] [Abstract][Full Text] [Related]
5. Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis.
Rodrigues L; Villellas C; Bailo R; Viveiros M; Aínsa JA
Antimicrob Agents Chemother; 2013 Feb; 57(2):751-7. PubMed ID: 23165464
[TBL] [Abstract][Full Text] [Related]
6. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.
Rodrigues L; Machado D; Couto I; Amaral L; Viveiros M
Infect Genet Evol; 2012 Jun; 12(4):695-700. PubMed ID: 21871582
[TBL] [Abstract][Full Text] [Related]
7. Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
Pieroni M; Machado D; Azzali E; Santos Costa S; Couto I; Costantino G; Viveiros M
J Med Chem; 2015 Aug; 58(15):5842-53. PubMed ID: 26197353
[TBL] [Abstract][Full Text] [Related]
8. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.
Hegeto LA; Caleffi-Ferracioli KR; Nakamura-Vasconcelos SS; Almeida AL; Baldin VP; Nakamura CV; Siqueira VLD; Scodro RBL; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():35-40. PubMed ID: 30029912
[TBL] [Abstract][Full Text] [Related]
9. Contribution of putative efflux pump genes to isoniazid resistance in clinical isolates of
Narang A; Giri A; Gupta S; Garima K; Bose M; Varma-Basil M
Int J Mycobacteriol; 2017; 6(2):177-183. PubMed ID: 28559521
[TBL] [Abstract][Full Text] [Related]
10. Carvacrol activity & morphological changes in Mycobacterium tuberculosis.
Nakamura de Vasconcelos SS; Caleffi-Ferracioli KR; Hegeto LA; Baldin VP; Nakamura CV; Stefanello TF; Freitas Gauze G; Yamazaki DA; Scodro RB; Siqueira VL; Cardoso RF
Future Microbiol; 2018 Jun; 13():877-888. PubMed ID: 29877104
[TBL] [Abstract][Full Text] [Related]
11. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
[TBL] [Abstract][Full Text] [Related]
12. Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.
Jang J; Kim R; Woo M; Jeong J; Park DE; Kim G; Delorme V
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416541
[TBL] [Abstract][Full Text] [Related]
13. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
Ramón-García S; Martín C; Thompson CJ; Aínsa JA
Antimicrob Agents Chemother; 2009 Sep; 53(9):3675-82. PubMed ID: 19564371
[TBL] [Abstract][Full Text] [Related]
14. Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
Dixit PP; Dixit PP; Thore SN
Eur J Med Chem; 2016 Jan; 107():38-47. PubMed ID: 26562541
[TBL] [Abstract][Full Text] [Related]
15. Molecular modelling and competitive inhibition of a Mycobacterium tuberculosis multidrug-resistance efflux pump.
Scaini JLR; Camargo AD; Seus VR; von Groll A; Werhli AV; da Silva PEA; Machado KDS
J Mol Graph Model; 2019 Mar; 87():98-108. PubMed ID: 30529931
[TBL] [Abstract][Full Text] [Related]
16. Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination.
Caleffi-Ferracioli KR; Amaral RC; Demitto FO; Maltempe FG; Canezin PH; Scodro RB; Nakamura CV; Leite CQ; Siqueira VL; Cardoso RF
Tuberculosis (Edinb); 2016 Mar; 97():65-72. PubMed ID: 26980498
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
18. In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis.
Biswas SS; Browne RB; Borah VV; Roy JD
Appl Biochem Biotechnol; 2021 Jun; 193(6):1757-1779. PubMed ID: 33826064
[TBL] [Abstract][Full Text] [Related]
19. MmpS5/MmpL5 as an efflux pump in Mycobacterium species.
Briffotaux J; Huang W; Wang X; Gicquel B
Tuberculosis (Edinb); 2017 Dec; 107():13-19. PubMed ID: 29050760
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Enhancers of Isoniazid Toxicity in
Lentz F; Reiling N; Martins A; Molnár J; Hilgeroth A
Molecules; 2018 Apr; 23(4):. PubMed ID: 29617279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
